---
schema_version: "secwatch.filing_event.v1"
accession: "0001974640-26-000001"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:49:49.219627+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Apogee Therapeutics FY2025 net loss $255.8M; cash $902.9M; zumilokibart milestones

## Summary
- Net loss $255.8M (FY2024: $182.1M); R&D expense $214.7M (FY2024: $167.9M).
- Cash, equivalents and marketable securities $902.9M; runway into 2H 2028.
- APEX Phase 2 Part A 52-week AD data expected March 2026; Part B 16-week data Q2 2026.
- Phase 3 AD initiation planned 2H 2026; asthma and EoE trial details later in 2026.
- Phase 1b head-to-head APG279 vs DUPIXENT in AD interim data anticipated 2H 2026.

## SEC filing metadata
- accession: 0001974640-26-000001
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000197464026000001/0001974640-26-000001-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000197464026000001/apge-20260302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001974640-26-000001
- JSON: https://secwatch.observer/filing/0001974640-26-000001.json
- Plain text: https://secwatch.observer/filing/0001974640-26-000001.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.